Initiator Pharma
Manufacturing · Denmark · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Ole Maaløes Vej 3, København N, Capital ...Phone Number
+45 61260035Website
www.initiatorpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage life science company focused on developing innovative drugs to address unmet medical needs in the central and peripheral nervous system. The company has a diverse pipeline that includes clinical programs targeting conditions such as erectile dysfunction, vulvodynia, and female sexual dysfunction. Their unique approach involves monoamine reuptake inhibitors aimed at enhancing neurotransmitter levels. Initiator Pharma's intended clients include individuals suffering from these conditions, particularly those who have not responded to existing therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Initiator Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Initiator Pharma
Check if Initiator Pharma has recently received funding, and reach out quickly before it becomes old news!
Initiator Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Initiator Pharma launches new products
Funding: Get notified immidiatlly once Initiator Pharma has new funding data
Click to see if Initiator Pharma had a recent Job posting/layoffs
Check out if Initiator Pharma is spiking on competitors!
Earning: See what the market has to say on Initiator Pharma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Initiator Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Initiator Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Initiator Pharma.
Initiator Pharma financials insights
Gather financial insights about Initiator Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$2.7M
Initiator Pharma Tech Stack
A closer look at the technologies used by Initiator Pharma
Initiator Pharma News & Media
The board of directors of Initiator Pharma A/S resolves on a rights issue amounting to SEK 56m
The board of directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, based on the authorisation from the general meeting held on 24 May 2024, resolved on a new issue of shares with pre-emption rights for the Company’s existing shareholders amounting to approximately SEK 56.2 mil…Initiator Pharma A/S has been approved for listing on the Nasdaq First North Growth Market
Initiator Pharma A/S (“Initiator” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021. Nasdaq Stockholm today announced that Initiator Pharma meets the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of tradingCorrection of previously published press release regarding CTA-filing for Phase I study
The press release published by Initiator Pharma at 03:52 p.m. today, October 19, 2021, “Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects ”, included incorrect information regarding the names of Initiator Pharma’s clinical programs. A corrected version of the press release is as follows. Initiator Pharma files CTA for Phase I study for the IPTN2021 program in relation to assessment of pain reducing effects InitiatorInitiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects
Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today that it has filed a Clinical Trials Application for its planned Phase I study with IP2105 in healthy subjects challenged with pain inducing ingredient (capsaicin) Initiator Pharma has filed its Clinical Trial Application (CTA) for its planned Phase I study in healthy male subjects with IP2015 to the Medicines & Healthcare products Regulatory Agency, MHRA, UK. Subject inclusion and dosing is expected January 2022. The
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Initiator Pharma
Sign Up For FreeTo access detailed company insights
Initiator Pharma A/S is a Danish clinical stage life science company focused on developing innovative drugs to address unmet medical needs in the central and peripheral nervous system. The company has a diverse pipeline that includes clinical programs targeting conditions such as erectile dysfunction, vulvodynia, and female sexual dysfunction. Thei... Read More
